ID   VGFR2_HUMAN             Reviewed;        1356 AA.
AC   P35968; A2RRS0; B5A925; C5IFA0; O60723; Q14178;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   12-OCT-2022, entry version 236.
DE   RecName: Full=Vascular endothelial growth factor receptor 2 {ECO:0000305};
DE            Short=VEGFR-2;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:10037737, ECO:0000269|PubMed:10102632};
DE   AltName: Full=Fetal liver kinase 1;
DE            Short=FLK-1;
DE   AltName: Full=Kinase insert domain receptor;
DE            Short=KDR;
DE   AltName: Full=Protein-tyrosine kinase receptor flk-1;
DE   AltName: CD_antigen=CD309;
DE   Flags: Precursor;
GN   Name=KDR {ECO:0000312|HGNC:HGNC:6307}; Synonyms=FLK1, VEGFR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INTERACTION WITH VEGFC, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION IN INHIBITION OF
RP   LYMPHANGIOGENESIS, INTERACTION WITH VEGFC, AND TISSUE SPECIFICITY.
RX   PubMed=19668192; DOI=10.1038/nm.2018;
RA   Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S., Takeda A.,
RA   Baffi J.Z., Yamada K., Kaneko H., Green M.G., Chappell J., Wilting J.,
RA   Weich H.A., Yamagami S., Amano S., Mizuki N., Alexander J.S.,
RA   Peterson M.L., Brekken R.A., Hirashima M., Capoor S., Usui T., Ambati B.K.,
RA   Ambati J.;
RT   "Alternatively spliced vascular endothelial growth factor receptor-2 is an
RT   essential endogenous inhibitor of lymphatic vessel growth.";
RL   Nat. Med. 15:1023-1030(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Yin L.Y., Wu Y., Patterson C.;
RT   "Full length human KDR/flk-1 sequence.";
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical vein;
RA   Yu Y., Whitney R.G., Sato J.D.;
RT   "Coding region for human VEGF receptor KDR (VEGFR-2).";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HIS-472.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-1356 (ISOFORM 1), AND VARIANT GLU-848.
RC   TISSUE=Umbilical vein;
RX   PubMed=1656371;
RA   Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L.,
RA   Shows T.B.;
RT   "Identification of a new endothelial cell growth factor receptor tyrosine
RT   kinase.";
RL   Oncogene 6:1677-1683(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7559454; DOI=10.1074/jbc.270.39.23111;
RA   Patterson C., Perrella M.A., Hsieh C.-M., Yoshizumi M., Lee M.-E.,
RA   Harber E.;
RT   "Cloning and functional analysis of the promoter for KDR/flk-1, a receptor
RT   for vascular endothelial growth factor.";
RL   J. Biol. Chem. 270:23111-23118(1995).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH VEGFA.
RX   PubMed=1417831; DOI=10.1016/0006-291x(92)90483-2;
RA   Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D.,
RA   Armellino D.C., Gospodarowicz D., Boehlen P.;
RT   "Identification of the KDR tyrosine kinase as a receptor for vascular
RT   endothelial cell growth factor.";
RL   Biochem. Biophys. Res. Commun. 187:1579-1586(1992).
RN   [10]
RP   FUNCTION AS VEGFA RECEPTOR; IN REGULATION OF CELL SHAPE; ACTIN CYTOSKELETON
RP   REORGANIZATION; CELL MIGRATION AND CELL PROLIFERATION, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=7929439; DOI=10.1016/s0021-9258(18)47116-5;
RA   Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H.;
RT   "Different signal transduction properties of KDR and Flt1, two receptors
RT   for vascular endothelial growth factor.";
RL   J. Biol. Chem. 269:26988-26995(1994).
RN   [11]
RP   FUNCTION IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG1; ACTIVATION OF MAP
RP   KINASES AND IN PROMOTING PROLIFERATION OF ENDOTHELIAL CELLS, INTERACTION
RP   WITH VEGFA AND PLCG1, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND
RP   GLYCOSYLATION.
RX   PubMed=9160888; DOI=10.1038/sj.onc.1201047;
RA   Takahashi T., Shibuya M.;
RT   "The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-
RT   gamma pathway and partially induces mitotic signals in NIH3T3
RT   fibroblasts.";
RL   Oncogene 14:2079-2089(1997).
RN   [12]
RP   FUNCTION IN INDUCTION OF NOS2 AND NOS3.
RX   PubMed=9837777; DOI=10.1006/bbrc.1998.9719;
RA   Kroll J., Waltenberger J.;
RT   "VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF
RT   receptor-2 (KDR).";
RL   Biochem. Biophys. Res. Commun. 252:743-746(1998).
RN   [13]
RP   FUNCTION IN ACTIVATION OF THE PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1
RP   SIGNALING PATHWAY.
RX   PubMed=9804796; DOI=10.1074/jbc.273.46.30336;
RA   Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V.,
RA   Ferrara N.;
RT   "Vascular endothelial growth factor regulates endothelial cell survival
RT   through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.
RT   Requirement for Flk-1/KDR activation.";
RL   J. Biol. Chem. 273:30336-30343(1998).
RN   [14]
RP   FUNCTION IN NITRIC OXIDE RELEASE.
RX   PubMed=10600473; DOI=10.1006/bbrc.1999.1729;
RA   Kroll J., Waltenberger J.;
RT   "A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide
RT   in response to VEGF-A stimulation in endothelial cells.";
RL   Biochem. Biophys. Res. Commun. 265:636-639(1999).
RN   [15]
RP   CATALYTIC ACTIVITY, CHARACTERIZATION OF VARIANT GLU-848, PHOSPHORYLATION AT
RP   TYR-1054 AND TYR-1059, AND ACTIVITY REGULATION.
RX   PubMed=10037737; DOI=10.1074/jbc.274.10.6453;
RA   Kendall R.L., Rutledge R.Z., Mao X., Tebben A.J., Hungate R.W.,
RA   Thomas K.A.;
RT   "Vascular endothelial growth factor receptor KDR tyrosine kinase activity
RT   is increased by autophosphorylation of two activation loop tyrosine
RT   residues.";
RL   J. Biol. Chem. 274:6453-6460(1999).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG1 AND PTK2/FAK1, INTERACTION WITH VEGFA,
RP   CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-996; TYR-1054 AND TYR-1059,
RP   MUTAGENESIS OF TYR-996; TYR-1054 AND TYR-1059, SUBCELLULAR LOCATION, AND
RP   ACTIVITY REGULATION.
RX   PubMed=10102632; DOI=10.1038/sj.onc.1202478;
RA   Dougher M., Terman B.I.;
RT   "Autophosphorylation of KDR in the kinase domain is required for maximal
RT   VEGF-stimulated kinase activity and receptor internalization.";
RL   Oncogene 18:1619-1627(1999).
RN   [17]
RP   INTERACTION WITH HIV-1 TAT (MICROBIAL INFECTION).
RX   PubMed=10590123; DOI=10.1128/jvi.74.1.344-353.2000;
RA   Mitola S., Soldi R., Zanon I., Barra L., Gutierrez M.I., Berkhout B.,
RA   Giacca M., Bussolino F.;
RT   "Identification of specific molecular structures of human immunodeficiency
RT   virus type 1 Tat relevant for its biological effects on vascular
RT   endothelial cells.";
RL   J. Virol. 74:344-353(2000).
RN   [18]
RP   FUNCTION IN ENDOTHELIAL CELL PROLIFERATION; PHOSPHORYLATION OF PLCG1 AND
RP   ACTIVATION OF MAP KINASES, PHOSPHORYLATION AT TYR-1175 AND TYR-1214, AND
RP   MUTAGENESIS OF LYS-868 AND TYR-1175.
RX   PubMed=11387210; DOI=10.1093/emboj/20.11.2768;
RA   Takahashi T., Yamaguchi S., Chida K., Shibuya M.;
RT   "A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-
RT   dependent activation of PLC-gamma and DNA synthesis in vascular endothelial
RT   cells.";
RL   EMBO J. 20:2768-2778(2001).
RN   [19]
RP   UBIQUITINATION, FUNCTION IN NITRIC OXIDE PRODUCTION, SUBCELLULAR LOCATION,
RP   AND INTERACTION WITH CBL.
RX   PubMed=12649282; DOI=10.1074/jbc.m301410200;
RA   Duval M., Bedard-Goulet S., Delisle C., Gratton J.P.;
RT   "Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR
RT   involves Cbl-mediated ubiquitination. Consequences on nitric oxide
RT   production from endothelial cells.";
RL   J. Biol. Chem. 278:20091-20097(2003).
RN   [20]
RP   INTERACTION WITH FLT4.
RX   PubMed=12881528; DOI=10.1074/jbc.m304499200;
RA   Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C.,
RA   Alitalo K., Claesson-Welsh L.;
RT   "Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3)
RT   heterodimerization with VEGFR-2 in primary lymphatic endothelial cells
RT   regulates tyrosine phosphorylation sites.";
RL   J. Biol. Chem. 278:40973-40979(2003).
RN   [21]
RP   INTERACTION WITH SHB, AND FUNCTION IN CELL MIGRATION.
RX   PubMed=15026417; DOI=10.1074/jbc.m312729200;
RA   Holmqvist K., Cross M.J., Rolny C., Haegerkvist R., Rahimi N.,
RA   Matsumoto T., Claesson-Welsh L., Welsh M.;
RT   "The adaptor protein shb binds to tyrosine 1175 in vascular endothelial
RT   growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular
RT   migration.";
RL   J. Biol. Chem. 279:22267-22275(2004).
RN   [22]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=14991896; DOI=10.1002/path.1520;
RA   Fox S.B., Turley H., Cheale M., Blazquez C., Roberts H., James N., Cook N.,
RA   Harris A., Gatter K.;
RT   "Phosphorylated KDR is expressed in the neoplastic and stromal elements of
RT   human renal tumours and shuttles from cell membrane to nucleus.";
RL   J. Pathol. 202:313-320(2004).
RN   [23]
RP   INTERACTION WITH VEGFA AND VEGFD, PHOSPHORYLATION AT TYR-1054 AND TYR-1059,
RP   FUNCTION IN VEGFA AND VEGFD SIGNALING; ACTIVATION OF MAPK1/ERK2 AND
RP   MAPK3/ERK1; ACTIVATION OF AKT1; PHOSPHORYLATION OF PLCG1 AND NOS3;
RP   MODULATION OF INTRACELLULAR CA(2+) LEVELS; CELL SURVIVAL AND POSITIVE
RP   REGULATION OF CELL PROLIFERATION; CELL MIGRATION AND ANGIOGENESIS, AND
RP   ACTIVITY REGULATION.
RX   PubMed=15215251; DOI=10.1074/jbc.m401538200;
RA   Jia H., Bagherzadeh A., Bicknell R., Duchen M.R., Liu D., Zachary I.;
RT   "Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially
RT   regulate KDR-mediated signaling and biological function in vascular
RT   endothelial cells.";
RL   J. Biol. Chem. 279:36148-36157(2004).
RN   [24]
RP   FUNCTION IN CELL MIGRATION; PHOSPHORYLATION OF PLCG1; ACTIVATION OF
RP   MAPK1/ERK2; MAPK3/ERK1 AND THE MAP KINASES AND IN REGULATION OF ACTIN
RP   CYTOSKELETON REORGANIZATION, INTERACTION WITH SH2D2A/TSAD, PHOSPHORYLATION
RP   AT TYR-951; TYR-1054; TYR-1059; TYR-1214; TYR-1305; TYR-1309 AND TYR-1319,
RP   AND MUTAGENESIS OF TYR-951.
RX   PubMed=15962004; DOI=10.1038/sj.emboj.7600709;
RA   Matsumoto T., Bohman S., Dixelius J., Berge T., Dimberg A., Magnusson P.,
RA   Wang L., Wikner C., Qi J.H., Wernstedt C., Wu J., Bruheim S., Mugishima H.,
RA   Mukhopadhyay D., Spurkland A., Claesson-Welsh L.;
RT   "VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in
RT   tumor angiogenesis.";
RL   EMBO J. 24:2342-2353(2005).
RN   [25]
RP   FUNCTION IN ENDOTHELIAL CELL MIGRATION; ACTIVATION OF MAP KINASES AND IN
RP   PHOSPHORYLATION OF FYN; SRC AND NCK1, INTERACTION WITH GRB2; FYN AND NCK1,
RP   AND MUTAGENESIS OF TYR-1214.
RX   PubMed=16966330; DOI=10.1074/jbc.m603928200;
RA   Lamalice L., Houle F., Huot J.;
RT   "Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck
RT   and activation of Fyn leading to SAPK2/p38 activation and endothelial cell
RT   migration in response to VEGF.";
RL   J. Biol. Chem. 281:34009-34020(2006).
RN   [26]
RP   SUBCELLULAR LOCATION, UBIQUITINATION, AND DEGRADATION.
RX   PubMed=17004325; DOI=10.1111/j.1600-0854.2006.00462.x;
RA   Ewan L.C., Jopling H.M., Jia H., Mittar S., Bagherzadeh A., Howell G.J.,
RA   Walker J.H., Zachary I.C., Ponnambalam S.;
RT   "Intrinsic tyrosine kinase activity is required for vascular endothelial
RT   growth factor receptor 2 ubiquitination, sorting and degradation in
RT   endothelial cells.";
RL   Traffic 7:1270-1282(2006).
RN   [27]
RP   FUNCTION IN ACTIVATION OF AKT1; PHOSPHORYLATION OF PLCG1 AND NOS3 AND
RP   REGULATION OF NITRIC OXIDE PRODUCTION, PHOSPHORYLATION AT TYR-801, AND
RP   MUTAGENESIS OF TYR-801.
RX   PubMed=17303569; DOI=10.1074/jbc.m609048200;
RA   Blanes M.G., Oubaha M., Rautureau Y., Gratton J.P.;
RT   "Phosphorylation of tyrosine 801 of vascular endothelial growth factor
RT   receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase
RT   activation and nitric oxide release from endothelial cells.";
RL   J. Biol. Chem. 282:10660-10669(2007).
RN   [28]
RP   INTERACTION WITH DAB2IP.
RX   PubMed=19033661; DOI=10.1172/jci36168;
RA   Zhang H., He Y., Dai S., Xu Z., Luo Y., Wan T., Luo D., Jones D., Tang S.,
RA   Chen H., Sessa W.C., Min W.;
RT   "AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and
RT   inflammatory angiogenesis in mice.";
RL   J. Clin. Invest. 118:3904-3916(2008).
RN   [29]
RP   PHOSPHORYLATION AT TYR-951; TYR-1175 AND TYR-1214, AND DEPHOSPHORYLATION BY
RP   PTPRB.
RX   PubMed=19136612; DOI=10.1096/fj.08-123810;
RA   Mellberg S., Dimberg A., Bahram F., Hayashi M., Rennel E., Ameur A.,
RA   Westholm J.O., Larsson E., Lindahl P., Cross M.J., Claesson-Welsh L.;
RT   "Transcriptional profiling reveals a critical role for tyrosine phosphatase
RT   VE-PTP in regulation of VEGFR2 activity and endothelial cell
RT   morphogenesis.";
RL   FASEB J. 23:1490-1502(2009).
RN   [30]
RP   PHOSPHORYLATION AT TYR-801; TYR-951; TYR-996; TYR-1054; TYR-1059; TYR-1175
RP   AND TYR-1214; DEPHOSPHORYLATION AT TYR-951; TYR-996; TYR-1054; TYR-1059;
RP   TYR-1175 AND TYR-1214 BY PTPRJ.
RX   PubMed=18936167; DOI=10.1128/mcb.01374-08;
RA   Chabot C., Spring K., Gratton J.P., Elchebly M., Royal I.;
RT   "New role for the protein tyrosine phosphatase DEP-1 in Akt activation and
RT   endothelial cell survival.";
RL   Mol. Cell. Biol. 29:241-253(2009).
RN   [31]
RP   FUNCTION AS VEGFA RECEPTOR IN TUMOR ANGIOGENESIS, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=19834490; DOI=10.1038/cdd.2009.152;
RA   Zhang Z., Neiva K.G., Lingen M.W., Ellis L.M., Nor J.E.;
RT   "VEGF-dependent tumor angiogenesis requires inverse and reciprocal
RT   regulation of VEGFR1 and VEGFR2.";
RL   Cell Death Differ. 17:499-512(2010).
RN   [32]
RP   FUNCTION IN LYMPHANGIOGENESIS (ISOFORM 2).
RX   PubMed=20179233; DOI=10.1158/1078-0432.ccr-09-1936;
RA   Becker J., Pavlakovic H., Ludewig F., Wilting F., Weich H.A.,
RA   Albuquerque R., Ambati J., Wilting J.;
RT   "Neuroblastoma progression correlates with downregulation of the
RT   lymphangiogenesis inhibitor sVEGFR-2.";
RL   Clin. Cancer Res. 16:1431-1441(2010).
RN   [33]
RP   INTERACTION WITH VEGFC AND FLT4, SUBCELLULAR LOCATION, AND FUNCTION IN
RP   ANGIOGENESIS.
RX   PubMed=20224550; DOI=10.1038/emboj.2010.30;
RA   Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M.,
RA   Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M.,
RA   Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L.;
RT   "VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on
RT   angiogenic sprouts.";
RL   EMBO J. 29:1377-1388(2010).
RN   [34]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21539813; DOI=10.1016/j.bbrc.2011.04.093;
RA   Jopling H.M., Howell G.J., Gamper N., Ponnambalam S.;
RT   "The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-
RT   plasma membrane recycling.";
RL   Biochem. Biophys. Res. Commun. 410:170-176(2011).
RN   [35]
RP   FUNCTION IN LYMPHANGIOGENESIS, AND INTERACTION WITH FLT4 AND VEGFC.
RX   PubMed=20705758; DOI=10.1182/blood-2010-02-267427;
RA   Nakao S., Zandi S., Hata Y., Kawahara S., Arita R., Schering A., Sun D.,
RA   Melhorn M.I., Ito Y., Lara-Castillo N., Ishibashi T., Hafezi-Moghadam A.;
RT   "Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous
RT   trapping mechanism links lymph- and angiogenesis.";
RL   Blood 117:1081-1090(2011).
RN   [36]
RP   REVIEW ON ROLE IN ANGIOGENESIS.
RX   PubMed=17002866; DOI=10.5483/bmbrep.2006.39.5.469;
RA   Shibuya M.;
RT   "Differential roles of vascular endothelial growth factor receptor-1 and
RT   receptor-2 in angiogenesis.";
RL   J. Biochem. Mol. Biol. 39:469-478(2006).
RN   [37]
RP   REVIEW.
RX   PubMed=17658244; DOI=10.1016/j.cellsig.2007.05.013;
RA   Holmes K., Roberts O.L., Thomas A.M., Cross M.J.;
RT   "Vascular endothelial growth factor receptor-2: structure, function,
RT   intracellular signalling and therapeutic inhibition.";
RL   Cell. Signal. 19:2003-2012(2007).
RN   [38]
RP   REVIEW ON STRUCTURE AND FUNCTION.
RX   PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121;
RA   Roskoski R. Jr.;
RT   "VEGF receptor protein-tyrosine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 375:287-291(2008).
RN   [39]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012;
RA   Lohela M., Bry M., Tammela T., Alitalo K.;
RT   "VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.";
RL   Curr. Opin. Cell Biol. 21:154-165(2009).
RN   [40]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=19761875; DOI=10.1016/j.bbapap.2009.09.002;
RA   Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K.;
RT   "Structure-function analysis of VEGF receptor activation and the role of
RT   coreceptors in angiogenic signaling.";
RL   Biochim. Biophys. Acta 1804:567-580(2010).
RN   [41]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=20462514; DOI=10.1016/j.bbcan.2010.04.004;
RA   Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R.;
RT   "Vascular endothelial growth factor receptor-2 in breast cancer.";
RL   Biochim. Biophys. Acta 1806:108-121(2010).
RN   [42]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=21779435; DOI=10.1177/1947601910392987;
RA   Shibuya M.;
RT   "Tyrosine kinase receptor Flt/VEGFR family: its characterization related to
RT   angiogenesis and cancer.";
RL   Genes Cancer 1:1119-1123(2010).
RN   [43]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=21711246; DOI=10.1042/bj20110301;
RA   Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.;
RT   "Signal transduction by vascular endothelial growth factor receptors.";
RL   Biochem. J. 437:169-183(2011).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-982 AND SER-984, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH PDCD6.
RX   PubMed=21893193; DOI=10.1016/j.cellsig.2011.08.013;
RA   Rho S.B., Song Y.J., Lim M.C., Lee S.H., Kim B.R., Park S.Y.;
RT   "Programmed cell death 6 (PDCD6) inhibits angiogenesis through
RT   PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2.";
RL   Cell. Signal. 24:131-139(2012).
RN   [46]
RP   ACTIVITY REGULATION, REDOX-ACTIVE DISULFIDE BOND, AND MUTAGENESIS OF
RP   CYS-1045.
RX   PubMed=23199280; DOI=10.1089/ars.2012.4565;
RA   Tao B.B., Liu S.Y., Zhang C.C., Fu W., Cai W.J., Wang Y., Shen Q.,
RA   Wang M.J., Chen Y., Zhang L.J., Zhu Y.Z., Zhu Y.C.;
RT   "VEGFR2 functions as an H(2)S-targeting receptor protein kinase with its
RT   novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch
RT   for hydrogen sulfide actions in vascular endothelial cells.";
RL   Antioxid. Redox Signal. 19:448-464(2013).
RN   [47]
RP   INTERACTION WITH ERN1, AND SUBCELLULAR LOCATION.
RX   PubMed=23529610; DOI=10.1161/circulationaha.112.001337;
RA   Zeng L., Xiao Q., Chen M., Margariti A., Martin D., Ivetic A., Xu H.,
RA   Mason J., Wang W., Cockerill G., Mori K., Li J.Y., Chien S., Hu Y., Xu Q.;
RT   "Vascular endothelial cell growth-activated XBP1 splicing in endothelial
RT   cells is crucial for angiogenesis.";
RL   Circulation 127:1712-1722(2013).
RN   [48]
RP   INTERACTION WITH PDCL3.
RX   PubMed=23792958; DOI=10.1074/jbc.m113.473173;
RA   Srinivasan S., Meyer R.D., Lugo R., Rahimi N.;
RT   "Identification of PDCL3 as a novel chaperone protein involved in the
RT   generation of functional VEGF receptor 2.";
RL   J. Biol. Chem. 288:23171-23181(2013).
RN   [49]
RP   INTERACTION WITH CCDC88A.
RX   PubMed=25187647; DOI=10.1091/mbc.e14-05-0978;
RA   Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M.,
RA   Kufareva I., Abagyan R., Ghosh P.;
RT   "Structural basis for activation of trimeric Gi proteins by multiple growth
RT   factor receptors via GIV/Girdin.";
RL   Mol. Biol. Cell 25:3654-3671(2014).
RN   [50]
RP   INTERACTION WITH PDCL3.
RX   PubMed=26059764; DOI=10.1007/s10456-015-9468-3;
RA   Srinivasan S., Chitalia V., Meyer R.D., Hartsough E., Mehta M., Harrold I.,
RA   Anderson N., Feng H., Smith L.E., Jiang Y., Costello C.E., Rahimi N.;
RT   "Hypoxia-induced expression of phosducin-like 3 regulates expression of
RT   VEGFR-2 and promotes angiogenesis.";
RL   Angiogenesis 18:449-462(2015).
RN   [51]
RP   FUNCTION, INTERACTION WITH BSG, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   PHOSPHORYLATION.
RX   PubMed=25825981; DOI=10.18632/oncotarget.2870;
RA   Khayati F., Perez-Cano L., Maouche K., Sadoux A., Boutalbi Z.,
RA   Podgorniak M.P., Maskos U., Setterblad N., Janin A., Calvo F., Lebbe C.,
RA   Menashi S., Fernandez-Recio J., Mourah S.;
RT   "EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by
RT   VEGF.";
RL   Oncotarget 6:9766-9780(2015).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 806-1171, FUNCTION,
RP   PHOSPHORYLATION AT TYR-1059, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10368301; DOI=10.1016/s0969-2126(99)80042-2;
RA   McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V.,
RA   Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.-C.,
RA   Villafranca J.E., Appelt K.;
RT   "Crystal structure of the kinase domain of human vascular endothelial
RT   growth factor receptor 2: a key enzyme in angiogenesis.";
RL   Structure 7:319-330(1999).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS) OF 806-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15837294; DOI=10.1016/j.bmcl.2005.03.034;
RA   Miyazaki Y., Matsunaga S., Tang J., Maeda Y., Nakano M., Philippe R.J.,
RA   Shibahara M., Liu W., Sato H., Wang L., Nolte R.T.;
RT   "Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual
RT   inhibitors.";
RL   Bioorg. Med. Chem. Lett. 15:2203-2207(2005).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 815-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=17253678; DOI=10.1021/jm061107l;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M.,
RA   Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R.,
RA   Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F., Polverino A.,
RA   Rose P., Tempest P., Wang L., Whittington D.A., Zhao H.;
RT   "Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine
RT   Tie-2 kinase inhibitor.";
RL   J. Med. Chem. 50:611-626(2007).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 806-1171 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR, AND FUNCTION.
RX   PubMed=18529047; DOI=10.1021/jm8001185;
RA   Peifer C., Selig R., Kinkel K., Ott D., Totzke F., Schaechtele C.,
RA   Heidenreich R., Roecken M., Schollmeyer D., Laufer S.;
RT   "Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-
RT   3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor
RT   receptor (VEGF-R) inhibitors.";
RL   J. Med. Chem. 51:3814-3824(2008).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 657-764, SUBUNIT,
RP   AUTOPHOSPHORYLATION, FUNCTION IN VEGFA SIGNALING AND ACTIVATION OF
RP   MAPK1/ERK2 AND MAPK3/ERK1, AND MUTAGENESIS OF ARG-726 AND ASP-731.
RX   PubMed=20080685; DOI=10.1073/pnas.0914052107;
RA   Yang Y., Xie P., Opatowsky Y., Schlessinger J.;
RT   "Direct contacts between extracellular membrane-proximal domains are
RT   required for VEGF receptor activation and cell signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:1906-1911(2010).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 120-326 IN COMPLEX WITH VEGFC,
RP   INTERACTION WITH VEGFC, DOMAIN, DISULFIDE BONDS, AND GLYCOSYLATION AT
RP   ASN-143; ASN-245 AND ASN-318.
RX   PubMed=20145116; DOI=10.1073/pnas.0914318107;
RA   Leppanen V.M., Prota A.E., Jeltsch M., Anisimov A., Kalkkinen N.,
RA   Strandin T., Lankinen H., Goldman A., Ballmer-Hofer K., Alitalo K.;
RT   "Structural determinants of growth factor binding and specificity by VEGF
RT   receptor 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2425-2430(2010).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 220-338 IN COMPLEX WITH ANTIBODY
RP   FRAGMENT, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-245 AND ASN-318.
RX   PubMed=21827946; DOI=10.1016/j.str.2011.01.019;
RA   Franklin M.C., Navarro E.C., Wang Y., Patel S., Singh P., Zhang Y.,
RA   Persaud K., Bari A., Griffith H., Shen L., Balderes P., Kussie P.;
RT   "The structural basis for the function of two anti-VEGF receptor 2
RT   antibodies.";
RL   Structure 19:1097-1107(2011).
RN   [59]
RP   VARIANT HCI SER-1147.
RX   PubMed=11807987; DOI=10.1002/gcc.10028;
RA   Walter J.W., North P.E., Waner M., Mizeracki A., Blei F., Walker J.W.T.,
RA   Reinisch J.F., Marchuk D.A.;
RT   "Somatic mutation of vascular endothelial growth factor receptors in
RT   juvenile hemangioma.";
RL   Genes Chromosomes Cancer 33:295-303(2002).
RN   [60]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-275 AND ARG-873.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [61]
RP   VARIANT HCI ARG-482, AND VARIANTS [LARGE SCALE ANALYSIS] ARG-2; MET-136;
RP   GLY-248; ILE-297; VAL-462; HIS-472; ARG-539; MET-689; ASN-814 AND THR-1065.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [62]
RP   VARIANT HCI ARG-482.
RX   PubMed=18931684; DOI=10.1038/nm.1877;
RA   Jinnin M., Medici D., Park L., Limaye N., Liu Y., Boscolo E., Bischoff J.,
RA   Vikkula M., Boye E., Olsen B.R.;
RT   "Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2
RT   signaling in infantile hemangioma.";
RL   Nat. Med. 14:1236-1246(2008).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor
CC       for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation
CC       of angiogenesis, vascular development, vascular permeability, and
CC       embryonic hematopoiesis. Promotes proliferation, survival, migration
CC       and differentiation of endothelial cells. Promotes reorganization of
CC       the actin cytoskeleton. Isoforms lacking a transmembrane domain, such
CC       as isoform 2 and isoform 3, may function as decoy receptors for VEGFA,
CC       VEGFC and/or VEGFD. Isoform 2 plays an important role as negative
CC       regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting
CC       the amount of free VEGFA and/or VEGFC and preventing their binding to
CC       FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers.
CC       Binding of vascular growth factors to isoform 1 leads to the activation
CC       of several signaling cascades. Activation of PLCG1 leads to the
CC       production of the cellular signaling molecules diacylglycerol and
CC       inositol 1,4,5-trisphosphate and the activation of protein kinase C.
CC       Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase
CC       signaling pathway, as well as of the AKT1 signaling pathway. Mediates
CC       phosphorylation of PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton
CC       and activation of PTK2/FAK1. Required for VEGFA-mediated induction of
CC       NOS2 and NOS3, leading to the production of the signaling molecule
CC       nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes
CC       phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
CC       {ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301,
CC       ECO:0000269|PubMed:10600473, ECO:0000269|PubMed:11387210,
CC       ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:1417831,
CC       ECO:0000269|PubMed:15026417, ECO:0000269|PubMed:15215251,
CC       ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:16966330,
CC       ECO:0000269|PubMed:17303569, ECO:0000269|PubMed:18529047,
CC       ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:19834490,
CC       ECO:0000269|PubMed:20080685, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:20705758, ECO:0000269|PubMed:21893193,
CC       ECO:0000269|PubMed:25825981, ECO:0000269|PubMed:7929439,
CC       ECO:0000269|PubMed:9160888, ECO:0000269|PubMed:9804796,
CC       ECO:0000269|PubMed:9837777}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:10037737, ECO:0000269|PubMed:10102632};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. Binding of VEGFA, VEGFC or VEGFD leads to dimerization
CC       and activation by autophosphorylation on tyrosine residues. Inhibited
CC       by the small molecule PTK inhibitor SU5614 ((3Z)-5-Chloro-3-[(3,5-
CC       dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one). May be
CC       regulated by hydrogen sulfide (H(2)S) levels via a H(2)S-sensitive
CC       intracellular disulfide bond. {ECO:0000269|PubMed:10037737,
CC       ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:15215251,
CC       ECO:0000269|PubMed:23199280}.
CC   -!- SUBUNIT: Homodimer in the presence of bound dimeric VEGFA, VEGFC or
CC       VEGFD ligands; monomeric in the absence of bound ligands. Can also form
CC       heterodimers with FLT1/VEGFR1 and KDR/VEGFR2. Interacts (tyrosine
CC       phosphorylated) with LFYN, NCK1, PLCG1. Interacts (tyrosine-
CC       phosphorylated active form preferentially) with DAB2IP (via C2 domain
CC       and active form preferentially); the interaction occurs at the late
CC       phase of VEGFA response and inhibits KDR/VEGFR2 activity. Interacts
CC       with SHBSH2D2A/TSAD, GRB2, MYOF, CBL and PDCD6. Interacts (via C-
CC       terminus domain) with ERN1 (via kinase domain); the interaction is
CC       facilitated in a XBP1 isoform 1- and vascular endothelial growth factor
CC       (VEGF)-dependent manner in endothelial cells (PubMed:23529610).
CC       Interacts (via juxtamembrane region) with chaperone PDCL3 (via
CC       thioredoxin fold region); the interaction leads to increased KDR/VEGFR2
CC       abundance through inhibition of its ubiquitination and degradation
CC       (PubMed:23792958, PubMed:26059764). Interacts (tyrosine phosphorylated)
CC       with CCDC88A/GIV (via SH2-like region); binding requires
CC       autophosphorylation of the KDR/VEGFR2 C-terminal region
CC       (PubMed:25187647). Interacts with isoform 2 of BSG (PubMed:25825981).
CC       {ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:12649282,
CC       ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:1417831,
CC       ECO:0000269|PubMed:15026417, ECO:0000269|PubMed:15215251,
CC       ECO:0000269|PubMed:15837294, ECO:0000269|PubMed:15962004,
CC       ECO:0000269|PubMed:16966330, ECO:0000269|PubMed:17253678,
CC       ECO:0000269|PubMed:18529047, ECO:0000269|PubMed:18593464,
CC       ECO:0000269|PubMed:19033661, ECO:0000269|PubMed:19668192,
CC       ECO:0000269|PubMed:20080685, ECO:0000269|PubMed:20145116,
CC       ECO:0000269|PubMed:20224550, ECO:0000269|PubMed:20705758,
CC       ECO:0000269|PubMed:21827946, ECO:0000269|PubMed:21893193,
CC       ECO:0000269|PubMed:23529610, ECO:0000269|PubMed:23792958,
CC       ECO:0000269|PubMed:25187647, ECO:0000269|PubMed:25825981,
CC       ECO:0000269|PubMed:26059764, ECO:0000269|PubMed:9160888}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Tat.
CC       {ECO:0000269|PubMed:10590123}.
CC   -!- INTERACTION:
CC       P35968; P35916: FLT4; NbExp=5; IntAct=EBI-1005487, EBI-1005467;
CC       P35968; O60565: GREM1; NbExp=4; IntAct=EBI-1005487, EBI-944395;
CC       P35968; P98160: HSPG2; NbExp=5; IntAct=EBI-1005487, EBI-947664;
CC       P35968; PRO_0000391621 [P98160]: HSPG2; NbExp=2; IntAct=EBI-1005487, EBI-6896259;
CC       P35968; PRO_0000391622 [P98160]: HSPG2; NbExp=2; IntAct=EBI-1005487, EBI-6896607;
CC       P35968; P17301: ITGA2; NbExp=2; IntAct=EBI-1005487, EBI-702960;
CC       P35968; P35968: KDR; NbExp=4; IntAct=EBI-1005487, EBI-1005487;
CC       P35968; O00629: KPNA4; NbExp=4; IntAct=EBI-1005487, EBI-396343;
CC       P35968; P09382: LGALS1; NbExp=3; IntAct=EBI-1005487, EBI-1048875;
CC       P35968; P08581: MET; NbExp=3; IntAct=EBI-1005487, EBI-1039152;
CC       P35968; P16333: NCK1; NbExp=3; IntAct=EBI-1005487, EBI-389883;
CC       P35968; O14786: NRP1; NbExp=2; IntAct=EBI-1005487, EBI-1187100;
CC       P35968; O75340: PDCD6; NbExp=4; IntAct=EBI-1005487, EBI-352915;
CC       P35968; P09619: PDGFRB; NbExp=2; IntAct=EBI-1005487, EBI-641237;
CC       P35968; P29350: PTPN6; NbExp=2; IntAct=EBI-1005487, EBI-78260;
CC       P35968; Q12913: PTPRJ; NbExp=4; IntAct=EBI-1005487, EBI-2264500;
CC       P35968; P12931: SRC; NbExp=6; IntAct=EBI-1005487, EBI-621482;
CC       P35968; P15692: VEGFA; NbExp=6; IntAct=EBI-1005487, EBI-1026643;
CC       P35968; P15692-4: VEGFA; NbExp=8; IntAct=EBI-1005487, EBI-1026691;
CC       P35968; P49767: VEGFC; NbExp=6; IntAct=EBI-1005487, EBI-3405539;
CC       P35968; Q9MYV3-3: VEGFA; Xeno; NbExp=2; IntAct=EBI-1005487, EBI-15622828;
CC   -!- SUBCELLULAR LOCATION: Cell junction {ECO:0000250}. Endoplasmic
CC       reticulum {ECO:0000269|PubMed:23529610}. Cell membrane
CC       {ECO:0000269|PubMed:25825981}. Note=Localized with RAP1A at cell-cell
CC       junctions (By similarity). Colocalizes with ERN1 and XBP1 in the
CC       endoplasmic reticulum in endothelial cells in a vascular endothelial
CC       growth factor (VEGF)-dependent manner (PubMed:23529610). {ECO:0000250,
CC       ECO:0000269|PubMed:23529610}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early
CC       endosome. Note=Detected on caveolae-enriched lipid rafts at the cell
CC       surface. Is recycled from the plasma membrane to endosomes and back
CC       again. Phosphorylation triggered by VEGFA binding promotes
CC       internalization and subsequent degradation. VEGFA binding triggers
CC       internalization and translocation to the nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=mbVegfr-2;
CC         IsoId=P35968-1; Sequence=Displayed;
CC       Name=2; Synonyms=sVegfr-2;
CC         IsoId=P35968-2; Sequence=VSP_041988, VSP_041989;
CC       Name=3; Synonyms=VEGFR2-712;
CC         IsoId=P35968-3; Sequence=VSP_041990, VSP_041991;
CC   -!- TISSUE SPECIFICITY: Detected in cornea (at protein level). Widely
CC       expressed. {ECO:0000269|PubMed:19668192}.
CC   -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFC binding.
CC       {ECO:0000269|PubMed:20145116}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20145116,
CC       ECO:0000269|PubMed:21827946, ECO:0000269|PubMed:9160888}.
CC   -!- PTM: Ubiquitinated. Tyrosine phosphorylation of the receptor promotes
CC       its poly-ubiquitination, leading to its degradation via the proteasome
CC       or lysosomal proteases. {ECO:0000269|PubMed:12649282,
CC       ECO:0000269|PubMed:17004325, ECO:0000269|PubMed:19834490}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the dimeric
CC       receptor phosphorylates tyrosine residues on the other subunit.
CC       Phosphorylation at Tyr-951 is important for interaction with
CC       SH2D2A/TSAD and VEGFA-mediated reorganization of the actin
CC       cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction
CC       with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for
CC       interaction with NCK1 and FYN. Dephosphorylated by PTPRB.
CC       Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-
CC       1175 and Tyr-1214. {ECO:0000269|PubMed:10037737,
CC       ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301,
CC       ECO:0000269|PubMed:11387210, ECO:0000269|PubMed:15215251,
CC       ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:18936167,
CC       ECO:0000269|PubMed:19136612, ECO:0000269|PubMed:25825981}.
CC   -!- PTM: The inhibitory disulfide bond between Cys-1024 and Cys-1045 may
CC       serve as a specific molecular switch for H(2)S-induced modification
CC       that regulates KDR/VEGFR2 function.
CC   -!- DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: A
CC       condition characterized by dull red, firm, dome-shaped hemangiomas,
CC       sharply demarcated from surrounding skin, usually presenting at birth
CC       or occurring within the first two or three months of life. They result
CC       from highly proliferative, localized growth of capillary endothelium
CC       and generally undergo regression and involution without scarring.
CC       {ECO:0000269|PubMed:11807987, ECO:0000269|PubMed:17344846,
CC       ECO:0000269|PubMed:18931684}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Plays a major role in tumor angiogenesis. In case of HIV-
CC       1 infection, the interaction with extracellular viral Tat protein seems
CC       to enhance angiogenesis in Kaposi's sarcoma lesions.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; EU826563; ACF47599.1; -; mRNA.
DR   EMBL; FJ899739; ACR78514.1; -; mRNA.
DR   EMBL; AF035121; AAB88005.1; -; mRNA.
DR   EMBL; AF063658; AAC16450.1; -; mRNA.
DR   EMBL; AC021220; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC111194; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC131822; AAI31823.1; -; mRNA.
DR   EMBL; L04947; AAA59459.1; -; mRNA.
DR   EMBL; X61656; CAA43837.1; -; mRNA.
DR   EMBL; X89776; CAA61916.1; -; Genomic_DNA.
DR   CCDS; CCDS3497.1; -. [P35968-1]
DR   PIR; JC1402; JC1402.
DR   RefSeq; NP_002244.1; NM_002253.2. [P35968-1]
DR   PDB; 1VR2; X-ray; 2.40 A; A=806-1171.
DR   PDB; 1Y6A; X-ray; 2.10 A; A=806-1171.
DR   PDB; 1Y6B; X-ray; 2.10 A; A=806-1171.
DR   PDB; 1YWN; X-ray; 1.71 A; A=806-1171.
DR   PDB; 2M59; NMR; -; A/B=759-795.
DR   PDB; 2MET; NMR; -; A/B/C=759-795.
DR   PDB; 2MEU; NMR; -; A/B=759-795.
DR   PDB; 2OH4; X-ray; 2.05 A; A=806-1171.
DR   PDB; 2P2H; X-ray; 1.95 A; A=815-1171.
DR   PDB; 2P2I; X-ray; 2.40 A; A/B=815-1171.
DR   PDB; 2QU5; X-ray; 2.95 A; A=815-1171.
DR   PDB; 2QU6; X-ray; 2.10 A; A/B=815-1171.
DR   PDB; 2RL5; X-ray; 2.65 A; A=815-1171.
DR   PDB; 2X1W; X-ray; 2.70 A; L/M/N/O=120-326.
DR   PDB; 2X1X; X-ray; 3.10 A; R=120-326.
DR   PDB; 2XIR; X-ray; 1.50 A; A=806-1171.
DR   PDB; 3B8Q; X-ray; 2.75 A; A/B=815-1171.
DR   PDB; 3B8R; X-ray; 2.70 A; A/B=815-1171.
DR   PDB; 3BE2; X-ray; 1.75 A; A=815-1171.
DR   PDB; 3C7Q; X-ray; 2.10 A; A=806-1171.
DR   PDB; 3CJF; X-ray; 2.15 A; A=806-1168.
DR   PDB; 3CJG; X-ray; 2.25 A; A=806-1168.
DR   PDB; 3CP9; X-ray; 2.50 A; A/B=815-1171.
DR   PDB; 3CPB; X-ray; 2.70 A; A/B=815-1171.
DR   PDB; 3CPC; X-ray; 2.40 A; A/B=815-1171.
DR   PDB; 3DTW; X-ray; 2.90 A; A/B=815-1171.
DR   PDB; 3EFL; X-ray; 2.20 A; A/B=815-1171.
DR   PDB; 3EWH; X-ray; 1.60 A; A=815-1171.
DR   PDB; 3KVQ; X-ray; 2.70 A; A=657-764.
DR   PDB; 3S35; X-ray; 2.20 A; X=220-338.
DR   PDB; 3S36; X-ray; 3.20 A; X=220-338.
DR   PDB; 3S37; X-ray; 2.70 A; X=220-338.
DR   PDB; 3U6J; X-ray; 2.15 A; A=815-1171.
DR   PDB; 3V2A; X-ray; 3.20 A; R=2-764.
DR   PDB; 3V6B; X-ray; 3.20 A; R=132-548.
DR   PDB; 3VHE; X-ray; 1.55 A; A=811-1169.
DR   PDB; 3VHK; X-ray; 2.49 A; A=806-1171.
DR   PDB; 3VID; X-ray; 2.30 A; A=813-1168.
DR   PDB; 3VNT; X-ray; 1.64 A; A=806-1171.
DR   PDB; 3VO3; X-ray; 1.52 A; A=806-1171.
DR   PDB; 3WZD; X-ray; 1.57 A; A=814-1172.
DR   PDB; 3WZE; X-ray; 1.90 A; A=814-1172.
DR   PDB; 4AG8; X-ray; 1.95 A; A=806-1171.
DR   PDB; 4AGC; X-ray; 2.00 A; A=787-1171.
DR   PDB; 4AGD; X-ray; 2.81 A; A=787-1171.
DR   PDB; 4ASD; X-ray; 2.03 A; A=787-1171.
DR   PDB; 4ASE; X-ray; 1.83 A; A=787-1171.
DR   PDB; 5EW3; X-ray; 2.50 A; A/B=806-1171.
DR   PDB; 5OYJ; X-ray; 2.38 A; C/D=326-549.
DR   PDB; 6GQO; X-ray; 1.87 A; A=806-939, A=991-1171.
DR   PDB; 6GQP; X-ray; 2.09 A; A=806-1171.
DR   PDB; 6GQQ; X-ray; 1.52 A; A=806-939, A=991-1171.
DR   PDB; 6XVJ; X-ray; 1.78 A; A=806-1171.
DR   PDB; 6XVK; X-ray; 1.99 A; A=806-1171.
DR   PDBsum; 1VR2; -.
DR   PDBsum; 1Y6A; -.
DR   PDBsum; 1Y6B; -.
DR   PDBsum; 1YWN; -.
DR   PDBsum; 2M59; -.
DR   PDBsum; 2MET; -.
DR   PDBsum; 2MEU; -.
DR   PDBsum; 2OH4; -.
DR   PDBsum; 2P2H; -.
DR   PDBsum; 2P2I; -.
DR   PDBsum; 2QU5; -.
DR   PDBsum; 2QU6; -.
DR   PDBsum; 2RL5; -.
DR   PDBsum; 2X1W; -.
DR   PDBsum; 2X1X; -.
DR   PDBsum; 2XIR; -.
DR   PDBsum; 3B8Q; -.
DR   PDBsum; 3B8R; -.
DR   PDBsum; 3BE2; -.
DR   PDBsum; 3C7Q; -.
DR   PDBsum; 3CJF; -.
DR   PDBsum; 3CJG; -.
DR   PDBsum; 3CP9; -.
DR   PDBsum; 3CPB; -.
DR   PDBsum; 3CPC; -.
DR   PDBsum; 3DTW; -.
DR   PDBsum; 3EFL; -.
DR   PDBsum; 3EWH; -.
DR   PDBsum; 3KVQ; -.
DR   PDBsum; 3S35; -.
DR   PDBsum; 3S36; -.
DR   PDBsum; 3S37; -.
DR   PDBsum; 3U6J; -.
DR   PDBsum; 3V2A; -.
DR   PDBsum; 3V6B; -.
DR   PDBsum; 3VHE; -.
DR   PDBsum; 3VHK; -.
DR   PDBsum; 3VID; -.
DR   PDBsum; 3VNT; -.
DR   PDBsum; 3VO3; -.
DR   PDBsum; 3WZD; -.
DR   PDBsum; 3WZE; -.
DR   PDBsum; 4AG8; -.
DR   PDBsum; 4AGC; -.
DR   PDBsum; 4AGD; -.
DR   PDBsum; 4ASD; -.
DR   PDBsum; 4ASE; -.
DR   PDBsum; 5EW3; -.
DR   PDBsum; 5OYJ; -.
DR   PDBsum; 6GQO; -.
DR   PDBsum; 6GQP; -.
DR   PDBsum; 6GQQ; -.
DR   PDBsum; 6XVJ; -.
DR   PDBsum; 6XVK; -.
DR   AlphaFoldDB; P35968; -.
DR   BMRB; P35968; -.
DR   SMR; P35968; -.
DR   BioGRID; 109992; 77.
DR   CORUM; P35968; -.
DR   DIP; DIP-486N; -.
DR   IntAct; P35968; 224.
DR   MINT; P35968; -.
DR   STRING; 9606.ENSP00000263923; -.
DR   BindingDB; P35968; -.
DR   ChEMBL; CHEMBL279; -.
DR   DrugBank; DB04727; 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea.
DR   DrugBank; DB07514; 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one.
DR   DrugBank; DB07528; 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one.
DR   DrugBank; DB06938; 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide.
DR   DrugBank; DB07326; 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB04849; Cediranib.
DR   DrugBank; DB05198; CYC116.
DR   DrugBank; DB12147; Erdafitinib.
DR   DrugBank; DB12307; Foretinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB06101; IMC-1C11.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB06080; Linifanib.
DR   DrugBank; DB06595; Midostaurin.
DR   DrugBank; DB07537; N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide.
DR   DrugBank; DB07183; N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide.
DR   DrugBank; DB07333; N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE.
DR   DrugBank; DB07334; N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE.
DR   DrugBank; DB07274; N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB08519; N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine.
DR   DrugBank; DB08042; N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB05931; Pegdinetanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugBank; DB05984; RAF-265.
DR   DrugBank; DB05578; Ramucirumab.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB14840; Ripretinib.
DR   DrugBank; DB06436; Semaxanib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05075; TG-100801.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB04879; Vatalanib.
DR   DrugBank; DB05146; XL820.
DR   DrugBank; DB05014; XL999.
DR   DrugCentral; P35968; -.
DR   GuidetoPHARMACOLOGY; 1813; -.
DR   CarbonylDB; P35968; -.
DR   GlyGen; P35968; 20 sites, 1 Thr glycan (1 site).
DR   iPTMnet; P35968; -.
DR   PhosphoSitePlus; P35968; -.
DR   BioMuta; KDR; -.
DR   DMDM; 9087218; -.
DR   EPD; P35968; -.
DR   jPOST; P35968; -.
DR   MassIVE; P35968; -.
DR   MaxQB; P35968; -.
DR   PaxDb; P35968; -.
DR   PeptideAtlas; P35968; -.
DR   PRIDE; P35968; -.
DR   ProteomicsDB; 55169; -. [P35968-1]
DR   ProteomicsDB; 55170; -. [P35968-2]
DR   ProteomicsDB; 55171; -. [P35968-3]
DR   ABCD; P35968; 72 sequenced antibodies.
DR   Antibodypedia; 3413; 3867 antibodies from 51 providers.
DR   DNASU; 3791; -.
DR   Ensembl; ENST00000263923.5; ENSP00000263923.4; ENSG00000128052.10. [P35968-1]
DR   GeneID; 3791; -.
DR   KEGG; hsa:3791; -.
DR   MANE-Select; ENST00000263923.5; ENSP00000263923.4; NM_002253.4; NP_002244.1.
DR   UCSC; uc003has.4; human. [P35968-1]
DR   CTD; 3791; -.
DR   DisGeNET; 3791; -.
DR   GeneCards; KDR; -.
DR   HGNC; HGNC:6307; KDR.
DR   HPA; ENSG00000128052; Low tissue specificity.
DR   MalaCards; KDR; -.
DR   MIM; 191306; gene.
DR   MIM; 602089; phenotype.
DR   neXtProt; NX_P35968; -.
DR   OpenTargets; ENSG00000128052; -.
DR   Orphanet; 464293; NON RARE IN EUROPE: Infantile capillary hemangioma.
DR   Orphanet; 3303; Tetralogy of Fallot.
DR   PharmGKB; PA30086; -.
DR   VEuPathDB; HostDB:ENSG00000128052; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000156710; -.
DR   HOGENOM; CLU_000288_49_4_1; -.
DR   InParanoid; P35968; -.
DR   OMA; RIFWDSK; -.
DR   PhylomeDB; P35968; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P35968; -.
DR   Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-9673768; Signaling by membrane-tethered fusions of PDGFRA or PDGFRB.
DR   SignaLink; P35968; -.
DR   SIGNOR; P35968; -.
DR   BioGRID-ORCS; 3791; 9 hits in 1116 CRISPR screens.
DR   EvolutionaryTrace; P35968; -.
DR   GeneWiki; Kinase_insert_domain_receptor; -.
DR   GenomeRNAi; 3791; -.
DR   Pharos; P35968; Tclin.
DR   PRO; PR:P35968; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P35968; protein.
DR   Bgee; ENSG00000128052; Expressed in germinal epithelium of ovary and 188 other tissues.
DR   Genevisible; P35968; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0030054; C:cell junction; ISS:UniProtKB.
DR   GO; GO:0005769; C:early endosome; ISS:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0097443; C:sorting endosome; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IPI:UniProtKB.
DR   GO; GO:0015026; F:coreceptor activity; IEA:Ensembl.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; TAS:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005178; F:integrin binding; IPI:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IBA:GO_Central.
DR   GO; GO:0060837; P:blood vessel endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0055074; P:calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; IMP:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; ISS:BHF-UCL.
DR   GO; GO:1904881; P:cellular response to hydrogen sulfide; IDA:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0003157; P:endocardium development; IEA:Ensembl.
DR   GO; GO:0045446; P:endothelial cell differentiation; IBA:GO_Central.
DR   GO; GO:0003158; P:endothelium development; ISS:UniProtKB.
DR   GO; GO:0002070; P:epithelial cell maturation; IEA:Ensembl.
DR   GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IBA:GO_Central.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0001945; P:lymph vessel development; IEA:Ensembl.
DR   GO; GO:0010463; P:mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; ISS:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IGI:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0051901; P:positive regulation of mitochondrial depolarization; IGI:MGI.
DR   GO; GO:0090141; P:positive regulation of mitochondrial fission; IGI:MGI.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl.
DR   GO; GO:2001214; P:positive regulation of vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:BHF-UCL.
DR   GO; GO:1903010; P:regulation of bone development; IEA:Ensembl.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:BHF-UCL.
DR   GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; IEA:Ensembl.
DR   GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0036324; P:vascular endothelial growth factor receptor-2 signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0061042; P:vascular wound healing; IMP:BHF-UCL.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 7.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR041348; VEGFR-2_TMD.
DR   InterPro; IPR009136; VEGFR2_rcpt.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF17988; VEGFR-2_TMD; 1.
DR   PRINTS; PR01834; VEGFRECEPTR2.
DR   SMART; SM00409; IG; 7.
DR   SMART; SM00408; IGc2; 5.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 6.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 5.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell junction; Cell membrane; Cytoplasm; Cytoplasmic vesicle;
KW   Developmental protein; Differentiation; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Host-virus interaction;
KW   Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   CHAIN           20..1356
FT                   /note="Vascular endothelial growth factor receptor 2"
FT                   /id="PRO_0000016771"
FT   TOPO_DOM        20..764
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        765..785
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        786..1356
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          46..110
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          141..207
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          224..320
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          328..414
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          421..548
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          551..660
FT                   /note="Ig-like C2-type 6"
FT   DOMAIN          667..753
FT                   /note="Ig-like C2-type 7"
FT   DOMAIN          834..1162
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1274..1318
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1292..1315
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1028
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         840..848
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   BINDING         868
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   SITE            1175
FT                   /note="Interaction with SHB"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         801
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:17303569,
FT                   ECO:0000269|PubMed:18936167"
FT   MOD_RES         951
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15962004,
FT                   ECO:0000269|PubMed:18936167, ECO:0000269|PubMed:19136612"
FT   MOD_RES         982
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         984
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         996
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10102632,
FT                   ECO:0000269|PubMed:18936167"
FT   MOD_RES         1054
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10037737,
FT                   ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:15215251,
FT                   ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:18936167"
FT   MOD_RES         1059
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10037737,
FT                   ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301,
FT                   ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:15962004,
FT                   ECO:0000269|PubMed:18936167"
FT   MOD_RES         1175
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11387210,
FT                   ECO:0000269|PubMed:18936167, ECO:0000269|PubMed:19136612"
FT   MOD_RES         1214
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11387210,
FT                   ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:18936167,
FT                   ECO:0000269|PubMed:19136612"
FT   MOD_RES         1231
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P35918"
FT   MOD_RES         1235
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P35918"
FT   MOD_RES         1238
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P35918"
FT   MOD_RES         1305
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15962004"
FT   MOD_RES         1309
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15962004"
FT   MOD_RES         1319
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15962004"
FT   CARBOHYD        46
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        66
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        96
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        143
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20145116"
FT   CARBOHYD        158
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        245
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20145116,
FT                   ECO:0000269|PubMed:21827946"
FT   CARBOHYD        318
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20145116,
FT                   ECO:0000269|PubMed:21827946"
FT   CARBOHYD        374
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        395
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        511
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        523
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        580
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        613
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        619
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        631
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        675
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        704
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        721
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        53..103
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        150..200
FT   DISULFID        246..307
FT   DISULFID        445..530
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        571..642
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        688..737
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        1024..1045
FT                   /note="Redox-active"
FT   VAR_SEQ         663..678
FT                   /note="ERVAPTITGNLENQTT -> GRETILDHCAEAVGMP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:19668192"
FT                   /id="VSP_041988"
FT   VAR_SEQ         679..1356
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:19668192"
FT                   /id="VSP_041989"
FT   VAR_SEQ         712
FT                   /note="G -> E (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_041990"
FT   VAR_SEQ         713..1356
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_041991"
FT   VARIANT         2
FT                   /note="Q -> R (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042053"
FT   VARIANT         136
FT                   /note="V -> M (in dbSNP:rs35636987)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042054"
FT   VARIANT         248
FT                   /note="A -> G (in a renal clear cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042055"
FT   VARIANT         275
FT                   /note="R -> L (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036126"
FT   VARIANT         297
FT                   /note="V -> I (in dbSNP:rs2305948)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_022071"
FT   VARIANT         462
FT                   /note="L -> V (in dbSNP:rs56286620)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042056"
FT   VARIANT         472
FT                   /note="Q -> H (in dbSNP:rs1870377)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_020353"
FT   VARIANT         482
FT                   /note="C -> R (in HCI; associated with disease
FT                   susceptibility; expression of FLT1 in hemangioma
FT                   endothelial cells is markedly reduced and KDR activity is
FT                   increased compared to controls; low FLT1 expression in
FT                   hemangioma cells is caused by reduced activity of a pathway
FT                   involving ITGB1, ANTXR1, KDR and NFATC2IP; the mutation
FT                   predicts to result in loss-of-function and disruption of
FT                   the normal association of these molecules;
FT                   dbSNP:rs34231037)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:18931684"
FT                   /id="VAR_042057"
FT   VARIANT         539
FT                   /note="G -> R (in dbSNP:rs55716939)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042058"
FT   VARIANT         689
FT                   /note="T -> M (in dbSNP:rs34038364)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042059"
FT   VARIANT         814
FT                   /note="D -> N (in dbSNP:rs35603373)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042060"
FT   VARIANT         848
FT                   /note="V -> E (strongly reduced autophosphorylation and
FT                   kinase activity; dbSNP:rs1139776)"
FT                   /evidence="ECO:0000269|PubMed:10037737,
FT                   ECO:0000269|PubMed:1656371"
FT                   /id="VAR_046679"
FT   VARIANT         873
FT                   /note="G -> R (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036127"
FT   VARIANT         952
FT                   /note="V -> I (in dbSNP:rs13129474)"
FT                   /id="VAR_046680"
FT   VARIANT         1065
FT                   /note="A -> T (in dbSNP:rs56302315)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042061"
FT   VARIANT         1147
FT                   /note="P -> S (in HCI; somatic mutation;
FT                   dbSNP:rs121917766)"
FT                   /evidence="ECO:0000269|PubMed:11807987"
FT                   /id="VAR_063147"
FT   MUTAGEN         726
FT                   /note="R->A: Strongly reduced autophosphorylation and
FT                   activation of MAP kinases."
FT                   /evidence="ECO:0000269|PubMed:20080685"
FT   MUTAGEN         731
FT                   /note="D->A: Strongly reduced autophosphorylation and
FT                   activation of MAP kinases."
FT                   /evidence="ECO:0000269|PubMed:20080685"
FT   MUTAGEN         801
FT                   /note="Y->F: Abolishes stimulation of nitric oxide
FT                   synthesis."
FT                   /evidence="ECO:0000269|PubMed:17303569"
FT   MUTAGEN         868
FT                   /note="K->M: Loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:11387210"
FT   MUTAGEN         951
FT                   /note="Y->F: Abolishes reorganization of the actin
FT                   cytoskeleton and cell migration in response to VEGFA."
FT                   /evidence="ECO:0000269|PubMed:15962004"
FT   MUTAGEN         996
FT                   /note="Y->F: Strongly reduced autophosphorylation. Reduces
FT                   phosphorylation of PLCG1."
FT                   /evidence="ECO:0000269|PubMed:10102632"
FT   MUTAGEN         1045
FT                   /note="C->A: Significantly higher kinase activity."
FT                   /evidence="ECO:0000269|PubMed:23199280"
FT   MUTAGEN         1054
FT                   /note="Y->F: Strongly reduced autophosphorylation.
FT                   Abolishes phosphorylation of downstream signaling proteins;
FT                   when associated with F-1059."
FT                   /evidence="ECO:0000269|PubMed:10102632"
FT   MUTAGEN         1059
FT                   /note="Y->F: Strongly reduced autophosphorylation.
FT                   Abolishes phosphorylation of downstream signaling proteins;
FT                   when associated with F-1054."
FT                   /evidence="ECO:0000269|PubMed:10102632"
FT   MUTAGEN         1175
FT                   /note="Y->F: Abolishes phosphorylation of PLCG1 and MAP
FT                   kinases in response to VEGFA."
FT                   /evidence="ECO:0000269|PubMed:11387210"
FT   MUTAGEN         1214
FT                   /note="Y->F: Loss of phosphorylation site. Abolishes
FT                   reorganization of the actin cytoskeleton in response to
FT                   VEGFA."
FT                   /evidence="ECO:0000269|PubMed:16966330"
FT   CONFLICT        2
FT                   /note="Q -> E (in Ref. 4; AAC16450)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        772
FT                   /note="A -> T (in Ref. 7; AAA59459/CAA43837)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        787
FT                   /note="R -> G (in Ref. 7; AAA59459/CAA43837)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        835
FT                   /note="K -> N (in Ref. 7; AAA59459/CAA43837)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1347
FT                   /note="S -> T (in Ref. 7; AAA59459/CAA43837)"
FT                   /evidence="ECO:0000305"
FT   STRAND          134..138
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          145..148
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          159..164
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   TURN            165..167
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          168..170
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          174..176
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          178..180
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   TURN            181..183
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          184..188
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   HELIX           189..191
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   TURN            192..194
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          196..202
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          207..210
FT                   /evidence="ECO:0007829|PDB:3V2A"
FT   STRAND          214..218
FT                   /evidence="ECO:0007829|PDB:2X1W"
FT   STRAND          223..230
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          234..238
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          242..250
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          252..254
FT                   /evidence="ECO:0007829|PDB:3V6B"
FT   STRAND          257..261
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   HELIX           269..272
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          273..276
FT                   /evidence="ECO:0007829|PDB:3V2A"
FT   STRAND          279..282
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          285..296
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   HELIX           299..301
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          303..310
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          315..328
FT                   /evidence="ECO:0007829|PDB:3S35"
FT   STRAND          338..343
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          348..351
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          354..358
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          361..366
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          377..387
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   HELIX           390..392
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          394..401
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   TURN            403..405
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          408..425
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          434..436
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          441..451
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          454..462
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   HELIX           463..465
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          482..484
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          497..499
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          503..507
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          510..521
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          526..534
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          537..548
FT                   /evidence="ECO:0007829|PDB:5OYJ"
FT   STRAND          676..679
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   STRAND          684..687
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   STRAND          697..706
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   STRAND          713..716
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   TURN            717..720
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   STRAND          721..724
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   HELIX           729..731
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   STRAND          733..740
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   STRAND          746..755
FT                   /evidence="ECO:0007829|PDB:3KVQ"
FT   HELIX           760..794
FT                   /evidence="ECO:0007829|PDB:2M59"
FT   STRAND          804..806
FT                   /evidence="ECO:0007829|PDB:4AGC"
FT   TURN            808..810
FT                   /evidence="ECO:0007829|PDB:4ASE"
FT   TURN            813..815
FT                   /evidence="ECO:0007829|PDB:3VHE"
FT   HELIX           817..819
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           824..827
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           831..833
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          834..842
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          844..858
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          862..870
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           876..892
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          901..905
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          907..910
FT                   /evidence="ECO:0007829|PDB:3WZD"
FT   STRAND          913..917
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           924..929
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   TURN            930..933
FT                   /evidence="ECO:0007829|PDB:3VO3"
FT   STRAND          934..936
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   TURN            995..998
FT                   /evidence="ECO:0007829|PDB:3VO3"
FT   HELIX           1002..1021
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          1024..1026
FT                   /evidence="ECO:0007829|PDB:4AGC"
FT   HELIX           1031..1033
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          1034..1036
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1038..1040
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          1042..1044
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1048..1050
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   TURN            1053..1055
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          1059..1062
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          1065..1067
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1069..1071
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1074..1079
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1084..1099
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   STRAND          1105..1108
FT                   /evidence="ECO:0007829|PDB:3C7Q"
FT   HELIX           1113..1121
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1133..1142
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1147..1149
FT                   /evidence="ECO:0007829|PDB:2XIR"
FT   HELIX           1153..1167
FT                   /evidence="ECO:0007829|PDB:2XIR"
SQ   SEQUENCE   1356 AA;  151527 MW;  59E7C44B05CFEBB3 CRC64;
     MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD
     WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD
     YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
     SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE
     KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
     DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP
     EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP
     PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY
     PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
     RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT
     PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT
     VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR
     NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL
     LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL
     GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN
     LLGACTKPGG PLMVIVEFCK FGNLSTYLRS KRNEFVPYKT KGARFRQGKD YVGAIPVDLK
     RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA
     SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDARLPLK WMAPETIFDR
     VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML
     DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS
     CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQTDS
     GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS
     SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV
//
